IFNA1 and cancer: A tentative approach to combining the proposed antiangiogenic effect of IFN, based on the persistency of drug availability in circulation, with the intermediate–high dose efficacy concept was the background of the European Organization for Research and Treatment of Cancer (EORTC) 18991 trial where pegylated IFN was the study drug.